Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04316429 · ClinicalTrials.gov registry record · NA

The Impact of Consumption of Eggs in the Context of Plant-Based Diets on Endothelial Function, Diet Quality, and Cardio-Metabolic Risk Factors in Adults at Risk for Type 2 Diabetes

A NA study of Type 2 Diabetes and Cardiovascular Diseases, sponsored by Griffin Hospital.

Completed
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT04316429: Completed NA study of Type 2 Diabetes and Cardiovascular Diseases, sponsored by Griffin Hospital.

NCT04316429 is a NA study of Type 2 Diabetes and Cardiovascular Diseases that has completed, run by Griffin Hospital. The registered enrollment target is 35 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04316429, a NA study of Type 2 Diabetes and Cardiovascular Diseases, has completed, sponsored by Griffin Hospital.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Purpose To assess the impact of inclusion of 2 eggs daily for 6 weeks in an otherwise vegan diet compared to a vegan diet on cardio-metabolic risk and dietary pattern in adults at risk for type 2 diabetes. Hypotheses In comparison with a vegan diet, the inclusion of 2 eggs daily in an otherwise vegan diet will improve or have neutral effects on endothelial function and other markers of cardio-metabolic risk in adults at risk for type 2 diabetes. (2) In comparison with a vegan diet, the inclusion of 2 eggs daily in an otherwise vegan diet will improve diet quality and nutrient intake in adults at risk for type 2 diabetes. (2) In comparison with a vegan diet, the inclusion of 2 eggs daily in an otherwise vegan diet will improve diet quality and nutrient intake in adults at risk for type 2 diabetes.

Primary Outcome

EF will be assessed at each of the 4 study visits and will be measured noninvasively in the right brachial artery by a high-frequency, 10-15 MHz, vascular ultrasound transducer (Philips iU22, Philips Medical Systems, Bothell, WA) in accordance with published guidelines. Endothelial function will be measured as Flow-mediated dilatation (FMD), that is the percent change in brachial artery diameter from pre-cuff inflation to 60-seconds post-cuff release. In addition to brachial diameter at 60 secon

Interventions

  • OTHER Egg included vegan phase
  • OTHER Vegan Phase

Study Locations (1)

Connecticut

  • Yale-Griffin Prevention Research Center - Derby

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2020-06-09
Est. Completion 2021-06-01
Phase NA
Griffin Hospital

22 total trials

What the finished NCT04316429 record still lists

NCT04316429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Egg included vegan phase is the first listed.

NCT04316429 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT04316429 about?

NCT04316429 is a clinical study titled "The Impact of Consumption of Eggs in the Context of Plant-Based Diets on Endothelial Function, Diet Quality, and Cardio-Metabolic Risk Factors in Adults at Risk for Type 2 Diabetes". Purpose To assess the impact of inclusion of 2 eggs daily for 6 weeks in an otherwise vegan diet compared to a vegan diet on cardio-metabolic risk and dietary pattern in adults at risk for type 2 diabetes. Hypotheses In comparison with a vegan diet, the inclusion of 2 eggs daily in an otherwise veg...

What is the current status of trial NCT04316429?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2020-06-09. Estimated completion is 2021-06-01.

What conditions does trial NCT04316429 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Cardiovascular Diseases.

What interventions are being tested in trial NCT04316429?

The interventions under investigation include: Egg included vegan phase (OTHER), Vegan Phase (OTHER).

Who is sponsoring clinical trial NCT04316429?

This trial is sponsored by Griffin Hospital, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04316429 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04316429's enrollment target sits among peer trials

35 246th of 327 higher than 79 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04316429, the US trial registry maintained by the National Library of Medicine. NCT04316429 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.